Corteva (NYSE:CTVA) Stock Rating Lowered by Wall Street Zen

Corteva (NYSE:CTVA) was downgraded by investment analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued to investors on Saturday.

Other equities research analysts have also recently issued research reports about the stock. Royal Bank Of Canada boosted their target price on shares of Corteva from $80.00 to $89.00 and gave the company an “outperform” rating in a research report on Thursday. BNP Paribas Exane raised their target price on shares of Corteva from $70.00 to $72.00 and gave the stock a “neutral” rating in a report on Monday, November 17th. Citigroup lifted their price target on shares of Corteva from $74.00 to $80.00 and gave the company a “neutral” rating in a research report on Thursday. Mizuho increased their price target on Corteva from $78.00 to $80.00 and gave the stock an “outperform” rating in a research report on Friday, January 16th. Finally, Oppenheimer set a $86.00 price objective on Corteva in a research note on Thursday. Two research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat.com, Corteva has an average rating of “Moderate Buy” and an average price target of $82.37.

Corteva Trading Up 0.2%

Shares of NYSE:CTVA opened at $72.63 on Friday. Corteva has a 12-month low of $53.40 and a 12-month high of $77.41. The business has a 50 day moving average of $68.82 and a 200-day moving average of $68.35. The company has a quick ratio of 0.96, a current ratio of 1.43 and a debt-to-equity ratio of 0.07. The stock has a market cap of $49.08 billion, a PE ratio of 45.97, a P/E/G ratio of 2.18 and a beta of 0.75.

Corteva (NYSE:CTVA) last released its quarterly earnings results on Tuesday, February 3rd. The company reported $0.22 earnings per share for the quarter, hitting the consensus estimate of $0.22. Corteva had a return on equity of 9.06% and a net margin of 6.29%.The business had revenue of $3.91 billion during the quarter, compared to analysts’ expectations of $4.23 billion. During the same period last year, the firm posted $0.32 EPS. The firm’s revenue for the quarter was down 1.7% compared to the same quarter last year. Corteva has set its FY 2026 guidance at 3.450-3.700 EPS. As a group, equities research analysts forecast that Corteva will post 2.96 earnings per share for the current year.

Institutional Trading of Corteva

Several large investors have recently bought and sold shares of the business. Gladwyn Financial Advisors Inc. bought a new position in shares of Corteva in the second quarter worth about $25,000. Total Investment Management Inc. acquired a new position in Corteva during the 2nd quarter worth approximately $27,000. Activest Wealth Management lifted its stake in Corteva by 118.3% in the 3rd quarter. Activest Wealth Management now owns 369 shares of the company’s stock valued at $25,000 after purchasing an additional 200 shares during the last quarter. Curat Global LLC boosted its position in Corteva by 93.7% in the second quarter. Curat Global LLC now owns 370 shares of the company’s stock valued at $28,000 after buying an additional 179 shares in the last quarter. Finally, JPL Wealth Management LLC acquired a new stake in Corteva in the third quarter valued at approximately $25,000. 81.54% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting Corteva

Here are the key news stories impacting Corteva this week:

• Positive Sentiment: Several sell‑side firms lifted targets and kept bullish ratings, signaling analyst confidence in longer‑term upside: Deutsche Bank to $90 (buy), Wolfe Research to $86 (outperform), and RBC to $89 (outperform). Deutsche Bank raise Wolfe Research raise RBC raise
• Positive Sentiment: Brokerage consensus remains constructive (consensus “Moderate Buy”), which supports demand for the shares despite near‑term noise. Consensus Moderate Buy
• Positive Sentiment: Strategic commentary highlights Corteva’s expanding role in global agriculture and technology leadership—positive for medium‑term growth expectations. Corteva expands role
• Neutral Sentiment: Analyst views are mixed across publications — some highlight long‑term upside tied to licensing and settlements, while others argue valuation limits near‑term gains. Investors should weigh catalyst timing. Bull case analysis Conflicting analyst views
• Neutral Sentiment: Technical analysis pieces warn of a key structural test — useful for traders but not definitive for fundamentals; could increase short‑term volatility. Technical caution
• Negative Sentiment: Q4 results missed revenue expectations (seasonal timing and weaker crop‑protection/seed demand); revenue miss and a wider loss drove an after‑hours selloff. Those operational misses are the main near‑term headwind. Q4 revenue miss After‑hours fall
• Negative Sentiment: JPMorgan downgraded Corteva from overweight to neutral (citing valuation/limited near‑term upside), which can cool momentum among institutional buyers. JPMorgan downgrade
• Negative Sentiment: Market reaction to the earnings miss (seasonal timing) and mixed guidance elements increases short‑term uncertainty even as analysts argue for longer‑term upside — expect higher intraday volatility. Seasonal timing impact

Corteva Company Profile

Corteva, Inc (NYSE: CTVA) is an independent global agriculture company that was established as a publicly traded firm in mid‑2019 following the separation of the agriculture businesses from DowDuPont. The company focuses on delivering technologies and products that help farmers increase productivity and manage crop health. Corteva’s operations combine seed genetics, crop protection chemistries, digital tools and biological solutions to address the full cycle of crop production.

Core business activities include research and development of seed genetics and trait technologies, formulation and sale of crop protection products (such as herbicides, insecticides and fungicides), and the development of seed treatments and biologicals.